{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:02:34Z","timestamp":1790240554265,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.thromres.2026.109832","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:35:17Z","timestamp":1788849317000},"page":"109832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Direct oral anticoagulants versus low-molecular-weight heparin in Asian patients with cancer-associated venous thromboembolism: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"265","author":[{"given":"Yee-Jen","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Ju","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Sheng","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.thromres.2026.109832_bb0005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40164-022-00331-9","article-title":"Safe and effective treatment of venous thromboembolism associated with Cancer: focus on direct Oral anticoagulants in Asian patients","volume":"11","author":"Lee","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"15","key":"10.1016\/j.thromres.2026.109832_bb0010","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1182\/bloodadvances.2022009577","article-title":"Survival after cancer-related venous thrombosis: the Scandinavian thrombosis and Cancer study","volume":"7","author":"Crobach","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2026.109832_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.669288","article-title":"Epidemiology of Cancer-associated thrombosis in Asia: a systematic review","volume":"8","author":"Lee","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.thromres.2026.109832_bb0020","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12885-015-1200-6","article-title":"Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study","volume":"15","author":"Chew","year":"2015","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.thromres.2026.109832_bb0025","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/j.1538-7836.2010.03873.x","article-title":"Incidence and cumulative recurrence rates of venous thromboembolism in the Taiwanese population","volume":"8","author":"Lee","year":"2010","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2026.109832_bb0030","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.thromres.2013.01.025","article-title":"The incidence, risk factors, and prognosis of recurrent venous thromboembolism (VTE) in patients with advanced solid cancers receiving anticoagulation therapy after the diagnosis of index VTE","volume":"131","author":"Yhim","year":"2013","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.thromres.2026.109832_bb0035","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.thromres.2026.109832_bb0040","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of Cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.thromres.2026.109832_bb0045","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral factor Xa inhibitor with low molecular weight heparin in patients with Cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.thromres.2026.109832_bb0050","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with Cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.thromres.2026.109832_bb0055","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/rth2.12359","article-title":"Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials","volume":"4","author":"Moik","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2026.109832_bb0060","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-022-01289-1","article-title":"Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Frere","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.thromres.2026.109832_bb0065","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.amjcard.2025.06.022","article-title":"Direct Oral anticoagulants versus low-molecular-weight heparin in patients with Cancer-associated thrombosis: a Meta-analysis of randomized controlled trials","volume":"254","author":"Mousavi","year":"2025","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.thromres.2026.109832_bb0070","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ejh.13453","article-title":"The efficacy and safety of DOACs versus LMWH for cancer-associated thrombosis: a systematic review and meta-analysis","volume":"105","author":"Tao","year":"2020","journal-title":"Eur. J. Haematol."},{"issue":"3","key":"10.1016\/j.thromres.2026.109832_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030559","article-title":"A phase II study to compare the safety and efficacy of direct Oral anticoagulants versus subcutaneous Dalteparin for Cancer-associated venous thromboembolism in patients with advanced upper gastrointestinal, hepatobiliary and pancreatic Cancer: PRIORITY","volume":"14","author":"Kim","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.thromres.2026.109832_bb0080","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1038\/s41467-024-50037-1","article-title":"Effectiveness and safety of continuous low-molecular-weight heparin versus switching to direct oral anticoagulants in cancer-associated venous thrombosis","volume":"15","author":"Kang","year":"2024","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.thromres.2026.109832_bb0085","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1055\/a-1886-5991","article-title":"Treatment and bleeding complications of Cancer-associated venous thromboembolism: a Korean population-based study","volume":"122","author":"Kim","year":"2022","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2026.109832_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71838","article-title":"Direct Oral anticoagulants versus low-molecular-weight heparin for treating venous thromboembolism in patients with gastrointestinal Cancer","volume":"15","author":"Chang","year":"2026","journal-title":"Cancer Med."},{"key":"10.1016\/j.thromres.2026.109832_bb0095","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620979575","article-title":"Treatment patterns and clinical outcomes in Korean cancer patients with venous thromboembolism: a retrospective cohort study","volume":"27","author":"Bang","year":"2021","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"2","key":"10.1016\/j.thromres.2026.109832_bb0100","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.36304","article-title":"Comparison between non-vitamin K antagonist Oral anticoagulants and low-molecular-weight heparin in Asian individuals with Cancer-associated venous thromboembolism","volume":"4","author":"Chen","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.thromres.2026.109832_bb0105","article-title":"Switching Cancer-associated venous thromboembolism treatment from continuous LMWH to DOACs: an evaluation","author":"Kang","year":"2026","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109832_bb0110","article-title":"Trends in anticoagulant utilization and clinical outcomes for cancer-associated thrombosis: a multicenter cohort study in Thailand's upper-middle-income country setting","volume":"10","author":"Kengkla","year":"2024","journal-title":"JCO Glob. Oncol."},{"issue":"1","key":"10.1016\/j.thromres.2026.109832_bb0115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12959-023-00453-y","article-title":"Comparison of the efficacy and safety of rivaroxaban and low-molecular-weight heparin in Chinese lung cancer patients with nonhigh-risk pulmonary embolism","volume":"21","author":"Song","year":"2023","journal-title":"Thromb. J."},{"issue":"3","key":"10.1016\/j.thromres.2026.109832_bb0120","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs Dalteparin in Cancer-associated thromboembolism: a randomized trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.thromres.2026.109832_bb0125","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"22","key":"10.1016\/j.thromres.2026.109832_bb0130","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct Oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with Cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.thromres.2026.109832_bb0135","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/ehjcvp\/pvaa067","article-title":"Efficacy and safety of direct oral anticoagulants vs. low molecular weight heparin for cancer-related venous thromboembolism: a meta-analysis of randomized trials","volume":"7","author":"Elbadawi","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"3","key":"10.1016\/j.thromres.2026.109832_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213940","article-title":"Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: a systematic review and network meta-analysis","volume":"14","author":"Rossel","year":"2019","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.thromres.2026.109832_bb0145","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/bloodadvances.2021006209","article-title":"Racial disparities in cancer-associated thrombosis","volume":"6","author":"Datta","year":"2022","journal-title":"Blood Adv."},{"issue":"11","key":"10.1016\/j.thromres.2026.109832_bb0150","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jacc.2024.06.023","article-title":"Competing risks in clinical trials: do they matter and how should we account for them?","volume":"84","author":"Gregson","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"issue":"23","key":"10.1016\/j.thromres.2026.109832_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11237159","article-title":"A comparison among nonvitamin K antagonist Oral anticoagulants in Asian patients with venous thromboembolism: a multi-institutional study","volume":"11","author":"Tsai","year":"2022","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.thromres.2026.109832_bb0160","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jaccao.2026.05.002","article-title":"A bleeding risk score for Cancer-associated venous thromboembolism in patients receiving direct Oral anticoagulants","volume":"8","author":"Nagai","year":"2026","journal-title":"JACC CardioOncol."},{"issue":"5","key":"10.1016\/j.thromres.2026.109832_bb0165","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1055\/s-0040-1720975","article-title":"Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study","volume":"121","author":"Ageno","year":"2021","journal-title":"Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.thromres.2026.109832_bb0170","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2510703","article-title":"Bleeding risk with Apixaban vs. rivaroxaban in acute venous thromboembolism","volume":"394","author":"Castellucci","year":"2026","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.thromres.2026.109832_bb0175","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaccao.2023.10.009","article-title":"Comparing anticoagulation strategies for venous thromboembolism associated with active Cancer: a systematic review and Meta-analysis","volume":"6","author":"Fujisaki","year":"2024","journal-title":"JACC CardioOncol."},{"issue":"1","key":"10.1016\/j.thromres.2026.109832_bb0180","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/cpt.1601","article-title":"Real-world rivaroxaban and Apixaban levels in Asian patients with atrial fibrillation","volume":"107","author":"Lin","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.thromres.2026.109832_bb0185","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ajh.25059","article-title":"Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer","volume":"93","author":"Streiff","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2026.109832_bb0190","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.thromres.2020.03.001","article-title":"Thirty-day outcomes in patients with proximal deep vein thrombosis who discontinued anticoagulant therapy prematurely","volume":"189","author":"Nieto","year":"2020","journal-title":"Thromb. Res."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826002513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826002513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:17:56Z","timestamp":1790237876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384826002513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":38,"alternative-id":["S0049384826002513"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109832","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct oral anticoagulants versus low-molecular-weight heparin in Asian patients with cancer-associated venous thromboembolism: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109832"}}